Plain-English translation of NCT05620628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications work better together than alone for people with advanced stomach cancer. The first medication is , which targets a specific protein called MET that is overactive in some stomach cancers. The second medication, , helps your immune system fight cancer cells by blocking a protein that tumors use to hide.
Most people with advanced stomach cancer don't respond well to current treatments, and the options available don't help enough people. This trial exists because early research suggests that using this medication alongside an immune-boosting treatment might slow cancer growth better than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You will take as a pill by mouth once daily (600 mg) in 28-day cycles. Every 4 weeks, you will receive as an intravenous infusion at a hospital or clinic. Every 8 weeks, doctors will perform scans to check how your cancer is responding to the treatment. The trial will continue as long as the treatment is helping and you can tolerate it.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
Jeeyun Lee
Enrollment target
~25 participants
Started
January 2023
Primary completion
December 2026
Age range
19 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jeeyun lee, Ph,MD
Samsung Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.